Doctronic reports that Foundayo, an oral GLP-1 for diabetes, shows promise but lacks long-term safety data beyond 68 weeks; ...
Sequencing CAR T-cell therapy versus bispecific antibodies in myeloma increasingly hinges on MRD depth, transplant candidacy, ...
Important progress across four clinical-stage programs demonstrating depth and breadth of obesity pipeline Initiated five late-stage global clinical trials in obesity, including the ribupatide injecti ...
One-time infusion of IMA203CD8 PRAME cell therapy in the ongoing Phase 1 dose escalation/dose expansion trial achieved anti-tumor activity in platinum-resistant ovarian cancer and in uterine cancer ...
MDS-UPDRS scores remained stable and durable across overall study population after 150 days of treatment with GT-02287 ...
CEO Abizer Gaslightwala highlights promising ASCO data demonstrating synergy of AKTX-101 with adagasrib in KRAS-driven cancers TAMPA, Fla. and LONDON, (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc ...
Remote job hunting can feel rough right now. A lot of listings are fake, vague, underpaid, or packed with hundreds of ...
Enrollment is tracking ahead of schedule, allowing potential acceleration of key trial milestonesMinimum enrollment to support interim analysis expected as soon as early July 2026Randomized, double-bl ...
New partnerships and in-state capabilities are reducing the need for cross-market travel while expanding access to CAR T-cell ...
Eli Lilly and Verve Therapeutics’ experimental gene-editing therapy VERVE-102 is showing promising results in lowering bad cholesterol with a single dose.
Immunovant's underlying bull case has now moved away from batoclimab and toward IMVT-1402. Find out why IMVT stock is upgraded to buy.
Despite a disappointing trial result, there's still a case for buying the stock, with a near-term catalyst on the horizon.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results